×
To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.
Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.
As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.
DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.
I had a question from a patient who had the musculoskeletal pain syndrome when I stopped imatinib for a trial of TFR. It was quite severe and they really don’t want to go through this again. However unfortunately I had to restart imatinib for a rising Bcr-Abl after which the pain syndrome ceased but replaced by a few chronic side effects from imatinib (cramp, GIT disturbance, oedema) and I have suggested changing to a 2nd generation drug. However they are very worried about getting the imatinib withdrawal syndrome again and wanted to know if it happens if one changes from imatinib to an alternative. I can’t recall any reports of this happening but do you know if there syndrome is only a problem with cessation of a TKI or could it be drug specific and might still occur if changing from imatinib to a 2nd generation TKI?
It is an interesting question. I have never seen this type of syndrome in a patient who switched to another TKI, but it could be confused with the initial toxicity features of the next TKI, I guess. I think it is very likely to be a TKI-wide effect, but we are still learning about the withdrawal syndrome. It would be interesting to hear from other clinicians about this issue.
ORIGINAL CASE:
I had a question from a patient who had the musculoskeletal pain syndrome when I stopped imatinib for a trial of TFR. It was quite severe and they really don’t want to go through this again. However unfortunately I had to restart imatinib for a rising Bcr-Abl after which the pain syndrome ceased but replaced by a few chronic side effects from imatinib (cramp, GIT disturbance, oedema) and I have suggested changing to a 2nd generation drug. However they are very worried about getting the imatinib withdrawal syndrome again and wanted to know if it happens if one changes from imatinib to an alternative. I can’t recall any reports of this happening but do you know if there syndrome is only a problem with cessation of a TKI or could it be drug specific and might still occur if changing from imatinib to a 2nd generation TKI?
I have not seen it. I do not believe that it is necessarily drug or patient specific. I have had a number of patients who have developed the syndrome after stopping imatinib, have subsequently gone on to dasatinib after relapsing and then stopped dasatinib, all on the TRAD discontinuation study and none of them have had recurrent symptoms.
But as Tim says, we still do not know a lot about the syndrome
This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.View our Privacy Policy